Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemotherapy Underused in Prostate Cancer

Publish date:: January 21, 2020

Key clinical point: One in four men in England and Wales with advanced prostate cancer receives chemotherapy.

Major finding: On average, 27% of men with advanced prostate cancer received docetaxel, ranging from 0% to 39% across National Health Service care providers in England.

Study details: The data come from the National Prostate Cancer Audit 2019 annual report for England and Wales.

Disclosures: Ms. Wise had no financial conflicts to disclose.

Citation:

Wise J. BMJ. 2020. doi:10.1136/bmj.m120.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Prostate Cancer

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,